<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00226980</url>
  </required_header>
  <id_info>
    <org_study_id>RENAL0001</org_study_id>
    <secondary_id>RENAL0001</secondary_id>
    <nct_id>NCT00226980</nct_id>
  </id_info>
  <brief_title>A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma</brief_title>
  <official_title>A Phase II Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of the combination of thalidomide and
      capecitabine in metastatic renal cell carcinoma and also to determine the safety of the
      combination.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of the combination of thalidomide and capecitabine in metastatic renal cell carcinoma.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of the combination</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Kidney Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:- Able to comprehend and sign an IRB approved Informed consent

          -  Willingness and ability to comply with the FDA-mandated S.T.E.P.S.Â® program.

          -  Male or female 18 years or older

          -  Willing to use contraception

          -  Pathologic diagnosis of renal cell carcinoma

          -  Bi-dimensionally measurable disease

          -  Evidence of disease progression prior to start of treatment

          -  Failed prior immunotherapy or unwilling/unable to receive prior immunotherapy

          -  Adequate hematologic data: ANC.1.5; platelets&gt;100x10^9

          -  Adequate renal function: Creatinine clearance .50cc

          -  Adequate liver function: Alkaline phos &lt;3XULN AST/ALT &lt;3XULN T.Bili &lt;1.5XULN

          -  ECOG performance status 0-1

        Exclusion Criteria:- Known brain metastases.

          -  Peripheral neuropathy.

          -  Pregnant and/ or lactating female.

          -  Unable to take a baby aspirin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Sandy Srinivas</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2005</study_first_posted>
  <last_update_submitted>April 10, 2009</last_update_submitted>
  <last_update_submitted_qc>April 10, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2009</last_update_posted>
  <responsible_party>
    <name_title>Sandy Srinivas, Principal Investigator</name_title>
    <organization>Stanford University School of Medicine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

